ContributorsPublishersAdvertisers

Frontline Tislelizumab Plus Chemo Improves OS in PD-L1+ Gastric or GEJ Cancers

onclive.com
 2022-01-24

Tislelizumab in combination with chemotherapy significantly improved overall survival vs chemotherapy alone when used in the frontline treatment of patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors expressed PD-L1, meeting the primary end point of the phase 3 RATIONALE 305 trial. Tislelizumab (BGB-A317)...

www.onclive.com

Comments / 0

Comments / 0